Pemvidutide News

health1 year ago•2 min saved

"Altimmune's New Weight-Loss Drug Minimizes Muscle Loss and Mimics Exercise Effects"

Altimmune has developed a new GLP-1 drug, pemvidutide, which helps patients lose 75% fat and only 25% muscle, unlike existing drugs like Ozempic and Mounjaro, which can lead to significant muscle loss. The drug combines a GLP-1 drug with another to mimic the effects of exercise, potentially offering a solution to the issue of muscle loss while on weight-loss medication. Other drugmakers, such as Eli Lilly, are also working on solutions to preserve muscle mass in patients using similar drugs.

via Business Insider|

#exercise-mimic #glp-1 #health

health2 years ago•5 min saved

"Promising Oral Drugs for Obesity and Diabetes: Twincretin and Danuglipron"

Pemvidutide, an investigational dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon, has shown significant weight loss and cardiometabolic benefits in a phase 2 trial. The drug is part of a growing group of incretin-based weight-loss drugs being developed, offering additional benefits beyond glucose control. Pemvidutide is being studied for the treatment of obesity and nonalcoholic steatohepatitis (NASH), while other drugs like tirzepatide and retatrutide are being explored for type 2 diabetes and fatty liver disease. The trial results showed substantial weight loss, reductions in cholesterol and triglyceride levels, and improvements in blood pressure without affecting glucose homeostasis. Gastrointestinal adverse events were common, but efforts will be made to reduce them in future trials. The full data for the trial will be announced later this year.

via Medscape|

#cardiometabolic-benefits #glp-1 #health